1. Home
  2. TR vs BLLN Comparison

TR vs BLLN Comparison

Compare TR & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tootsie Roll Industries Inc.

TR

Tootsie Roll Industries Inc.

HOLD

Current Price

$43.28

Market Cap

3.1B

ML Signal

HOLD

BLLN

BillionToOne Inc.

N/A

Current Price

$83.97

Market Cap

3.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TR
BLLN
Founded
1896
2016
Country
United States
United States
Employees
2100
713
Industry
Specialty Foods
Medical Specialities
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
3.7B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TR
BLLN
Price
$43.28
$83.97
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$126.71
AVG Volume (30 Days)
89.2K
343.3K
Earning Date
05-08-2026
05-06-2026
Dividend Yield
0.84%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$45.96
Revenue Next Year
N/A
$30.11
P/E Ratio
$32.36
N/A
Revenue Growth
N/A
N/A
52 Week Low
$31.17
$61.96
52 Week High
$45.06
$138.70

Technical Indicators

Market Signals
Indicator
TR
BLLN
Relative Strength Index (RSI) 49.22 54.03
Support Level $40.07 $79.33
Resistance Level $43.37 $83.20
Average True Range (ATR) 1.11 6.94
MACD -0.20 0.01
Stochastic Oscillator 26.50 50.23

Price Performance

Historical Comparison
TR
BLLN

About TR Tootsie Roll Industries Inc.

Tootsie Roll Industries Inc manufactures and sells confectionery products. Notable varieties include Tootsie Roll and Tootsie Pops, Charms, Blow-Pops, Dots, Junior Mints, Sugar Daddy and Sugar Babies, Andes, Dubble Bubble, Razzles among others. The company sells its products to wholesale distributors and directly to retail stores. Geographically, it generates a majority of its revenue from the United States and rest from Canada, Mexico and other regions.

About BLLN BillionToOne Inc.

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

Share on Social Networks: